Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2021-03-30 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 30, 2021. It announces that the FDA has approved Fast Track Designation for the company's drug Annamycin. The document includes a press release as Exhibit 99.1. The text explicitly states that the information is being furnished and shall not be deemed "filed" for purposes of the Exchange Act, indicating this is an announcement rather than a full report. The document length is 3686 characters, which is relatively short and consistent with an announcement rather than a detailed report. There are no financial statements or substantive financial data included. The content is primarily a regulatory announcement about a development related to the company's drug and FDA designation. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-30 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key section is Item 2.02, which states the company issued a press release announcing financial results for the year ended December 31, 2020. The document includes the press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3315 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an Earnings Release (ER) announcement rather than a full Annual Report (10-K) or Interim Report (IR).
2021-03-24 English
FORM 10-K
Annual Report FY 2020
2021-03-24 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 8, 2021, for Moleculin Biotech, Inc. It includes a Regulation FD Disclosure about an investor webinar and a press presentation (Exhibit 99.1). The text explicitly states that the information is being furnished and shall not be filed for purposes of the Exchange Act, indicating this is a regulatory announcement rather than a full financial report. The document length is 3415 characters, which is relatively short and consistent with a regulatory filing or announcement rather than a full report like an Annual or Quarterly Report. There is no substantive financial data or detailed financial statements included. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for SEC Form 8-K filings that do not fit other specific categories.
2021-03-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Moleculin Biotech, Inc. It reports on the company's compliance with Nasdaq's minimum bid price requirement after previously receiving a deficiency notice. The content is an update on a regulatory compliance event rather than a full financial report or detailed analysis. The document is relatively short (3868 characters) and focuses on a specific event related to listing compliance. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-19 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 10, 2021. It announces that the underwriters of a public offering exercised their option to purchase additional shares, increasing gross proceeds to approximately $78 million. The document includes a press release as an exhibit. The content focuses on a financing event related to the company's capital raising activities. There are no financial statements or detailed financial results presented, only an announcement of a financing transaction. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is 3308 characters, which is consistent with a brief announcement rather than a full report.
2021-02-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.